SOURCE: Shinesrooms.com

Shinesrooms.com

April 16, 2012 08:10 ET

Equity Research on Endo Pharmaceuticals Holdings Inc. and Allergan Inc. - Drug Manufacturers Acquiring and Expanding

NEW YORK, NY--(Marketwire - Apr 16, 2012) - www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Manufacturers - Other industry and are offering free analytical research on Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) and Allergan Inc. (NYSE: AGN). Register with us today at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index.com to have free access to these research reports.

As the age of the patent cliff continues, companies in the drug manufacturers - other industry have been looking to grow their sales through expansions and acquisitions. Some companies have also been focusing on product pipelines. However, these endeavors do not always bear fruit. Get your free reports on Endo Pharmaceuticals Holdings Inc. and Allergan Inc. at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.

www.shinesrooms.com is the Ultimate Trading Environment for investors. If you are considering owning Endo Pharmaceuticals Holdings Inc. and Allergan Inc. then you should sign up for a free membership and our complimentary reports today at www.shinesrooms.com. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Allergan Inc. is looking across the pond to grow sales, and will start an advertising campaign in Europe to promote its breast implants there. Allergan has also been looking into alternative uses for its Botox product, and recently announced encouraging data from two phase III trials that looked at the drug in patients with urinary incontinence. Allergan Inc. report is accessible for free by registering today at http://www.shinesrooms.com/AllerganInc160412.pdf.

On the acquisition side of things, Endo Pharmaceuticals Holdings Inc. has recently announced that it has purchased an oxymorphone patent from Johnson Matthey plc. The acquisition will increase patent protection for Endo's OPANA franchise. Endo has been involved in a number of other deals this year, and is doing an admirable job of increasing its holdings. Endo Pharmaceuticals Holdings Inc. report is accessible for free by registering today at http://www.shinesrooms.com/EndoPharmaceuticalsHoldingsInc160412.pdf.

The two Drug Manufacturers - Other stocks research reports are available for free by signing up now on www.shinesrooms.com.

About Shinesrooms.com

Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.

Contact Information